Global practices in PDX programs

G. Y. Ho, C. L. Scott, K. Pham

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

Abstract

Patient-derived xenograft (PDX) programs are crucial research tools in providing high-quality preclinical data for successful drug development, proof of principle of novel therapy efficacies, and the search for relevant biomarkers. These PDX programs are difficult to generate, costly to run and maintain, and must be able to change dynamically in line with technological and scientific advances. To date there are no specific guidelines for the development of a successful PDX program, particularly within the academic setting.The ultimate goal of most successful PDX programs is to generate high-quality research data that can be used to shape the landscape of novel oncologic therapies. The chance of success is increased by understanding the current PDX practices adopted by various research programs globally, and identifying key aspects of successful programs with a focus on areas for improvements.

Original languageEnglish
Title of host publicationPatient Derived Tumor Xenograft Models
Subtitle of host publicationPromise, Potential and Practice
EditorsRajesh Uthamanthil, Peggy Tinkey, Elisa de Stanchina
PublisherElsevier
Pages379-407
Number of pages29
ISBN (Electronic)9780128040614
ISBN (Print)9780128040102
DOIs
Publication statusPublished - 2017
Externally publishedYes

Keywords

  • Academia
  • Australia
  • Best practice
  • Commercialization
  • Europe
  • Global
  • Governance
  • North America
  • PDX characterization
  • PDX survey

Cite this